RxDoctor Payments DataLook up a doctor →

Andria Mushahwar, MD

Gastroenterology · Maitland, FLNPI 1023110814

Payments from drug & device makers

$636,293in general payments, 2019–2025

Across 1,074 payments — averaging $592.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$560K
  • Takeda Pharmaceuticals U.S.A., Inc.$19K
  • Pfizer$18K
  • Boehringer Ingelheim$11K
  • Bausch Health US, LLC$11K
  • Janssen Research & Development, LLC$4K
  • plus $14K from 43 others
$10,604in research payments, 2019–2025

Across 34 payments — averaging $311.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$7K
  • AbbVie$3K

What the payments were for

  • Consulting fees$5,6596%
  • Speaking & faculty fees$71,87571%
  • Travel & lodging$7,2487%
  • Food & beverage$16,54816%
  • Education$880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$636,293 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$57,082
Medicare patients
198
Services billed
391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide194$208,577
XifaxanRifaximin60$197,202
ZenpepLipase/Protease/Amylase32$94,124
CreonLipase/Protease/Amylase26$84,004
VemlidyTenofovir Alafenamide18$28,704
Ondansetron Hcl17$16,110
Dexlansoprazole DrDexlansoprazole48$11,409
Mesalamine16$9,221
MovantikNaloxegol Oxalate13$9,130
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl302$4,989
Famotidine329$4,237
Ursodiol11$2,947
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg66$1,521
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl77$1,340
Lubiprostone13$1,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$559,857$292,581220 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,346$197,20260 claims
Aimmune Therapeutics, Inc.Zenpep$278$94,12432 claims
GileadVemlidy$683$28,70418 claims
Redhill Biopharma Inc.Movantik$169$9,13013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Maitland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →